Omnicell (OMCL)
(Delayed Data from NSDQ)
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
Zacks News
Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Reasons to Add Patterson Companies (PDCO) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
Quest Diagnostics' (DGX) Base Business Grows Despite Margin Woes
by Zacks Equity Research
Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.
BD's (BDX) New Combination Test to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.
Catalent (CTLT) Expands Packaging Capabilities at Japan Facility
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in this key hub in its Asia-Pacific Clinical Supply Services network.
Exact Sciences (EXAS) Cologuard Growth Robust Amid Margin Woes
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business is growing on impressive Cologuard volume growth and revenue contributions from the PreventionGenetics acquisition.
Cardinal Health (CAH) Ties Up to Deliver Products Via Drones
by Zacks Equity Research
Cardinal Health's (CAH) latest collaboration is expected to significantly boost its distribution strategy and improve patient service.
3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.
Omnicell (OMCL) Up 10% Since Q1 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Omnicell's (OMCL) strategic partnerships and continued innovations for the Autonomous Pharmacy.
Illumina's (ILMN) GRAIL to Offer Galleri Test in Indianapolis
by Zacks Equity Research
Illumina's (ILMN) division GRAIL will offer the Galleri MCED blood test to eligible patients across the Community Health Network's care sites.
ENOV vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ENOV vs. OMCL: Which Stock Is the Better Value Option?
Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLYG
3 Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care
by Zacks Equity Research
Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.
Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
McKesson's (MCK) Latest JV to Boost Cancer Treatment Options
by Zacks Equity Research
McKesson's (MCK) latest activities in the oncology care space is expected to serve a wider patient pool.
Here's Why You Should Invest in AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to benefit from its broad range of services.
Zacks Industry Outlook Highlights Omnicell, Axonics and Outset Medical
by Zacks Equity Research
Omnicell, Axonics and Outset Medical have been highlighted in this Industry Outlook article.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Change Healthcare (CHNG)-Luma Launch Patient Engagement Suite
by Zacks Equity Research
Change Healthcare's (CHNG) latest launch is expected to significantly improve patients' healthcare journey and create a more streamlined patient experience.
3 Medical Info System Stocks Braving Industry Headwinds
by Urmimala Biswas
Medical Info Systems stocks like Omnicell, Inc. (OMCL), Axonics, Inc. (AXNX) and Outset Medical, Inc. (OM) are expected to gain despite pandemic-led disruptions.
Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG
Here's Why You Should Hold on to Inogen (INGN) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.